Anagrelidum
Anagrelide Vipharm contains the active substance anagrelide. Anagrelide inhibits platelet production. It reduces the production of platelets by the bone marrow, leading to a decrease in the number of platelets to a more normal value. For this reason, it is used to treat patients with essential thrombocythemia. Essential thrombocythemia is a disease that occurs when the bone marrow produces too many blood cells called platelets. An excess of platelets in the blood can lead to severe circulatory and blood clotting disorders.
Before starting anagrelide, talk to your doctor:
When taking anagrelide with acetylsalicylic acid (a component of many painkillers and antipyretics, as well as anti-coagulants, also known as aspirin), the risk of serious bleeding (bleeding) increases (see "Anagrelide Vipharm and other medicines"). Anagrelide Vipharm should be taken exactly as prescribed by your doctor. Do not stop taking the medicine without consulting your doctor first. Do not suddenly stop taking this medicine without consulting your doctor. Stopping the medicine suddenly can increase the risk of a stroke. Stroke symptoms can include sudden numbness or weakness of the face, arm, or leg, especially on one side of the body, sudden confusion, difficulty speaking or understanding speech, sudden vision problems in one or both eyes, sudden walking problems, dizziness, loss of balance or coordination, and sudden severe headache without a known cause. Seek medical help immediately.
Experience with Anagrelide Vipharm in children and adolescents is limited. Caution should be exercised when using.
Tell your doctor or pharmacist about all the medicines you are taking now or have taken recently, as well as any medicines you plan to take. Inform your doctor about taking any of the following medicines:
Anagrelide Vipharm or the above medicines may not work properly if taken together. If in doubt, consult your doctor or pharmacist.
If you are pregnant or planning to become pregnant, inform your doctor. Pregnant women should not take anagrelide. Women who may become pregnant should use effective contraception during anagrelide treatment. Your doctor can advise on contraception methods. Breastfeeding women or those planning to breastfeed should inform their doctor. Anagrelide should not be used during breastfeeding. You should stop breastfeeding if you are taking anagrelide.
Some patients taking anagrelide have experienced dizziness. If you experience dizziness, do not drive or operate machinery.
If you have been diagnosed with an intolerance to some sugars, contact your doctor before taking the medicine. The medicine contains less than 1 mmol (23 mg) of sodium per capsule, which means it is considered "sodium-free".
Take this medicine always as directed by your doctor. If you are unsure, consult your doctor or pharmacist. The amount of anagrelide taken by individual patients may vary and depends on the patient's condition. Your doctor will prescribe the appropriate dose for each patient. The usual starting dose of anagrelide is 1 mg. You take this dose as a 0.5 mg capsule twice a day for at least one week. After this period, your doctor may increase or decrease the number of capsules taken to establish the most suitable dose for you, which will provide the most effective treatment. Swallow the capsules whole with a glass of water. Do not crush the capsules or dissolve their contents in liquids. You can take the capsules with food, after food, or on an empty stomach. It is best to take the capsule(s) at the same time every day. Do nottake more or fewer capsules than your doctor has prescribed. Do notstop taking the medicine without consulting your doctor first. Do not suddenly stop taking this medicine. Your doctor will order regular blood tests to check if the medicine is working and if your liver and kidneys are working properly.
If you have taken more anagrelide than prescribed or if someone else has taken your medicine, contact your doctor or pharmacist immediately. Show them the medicine package.
Take the capsules as soon as you remember. Take the next dose at the usual time. Do not take a double dose to make up for a missed dose.
Like all medicines, Anagrelide Vipharm can cause side effects, although not everybody gets them. If you experience any worrying symptoms, consult your doctor. Serious side effects: Uncommon: heart failure (symptoms include shortness of breath, chest pain, swelling of the lower limbs due to fluid accumulation), serious heart rhythm disorders (ventricular tachycardia, supraventricular tachycardia, or atrial fibrillation),
Rare: kidney failure (passing very little urine or urine retention), heart attack. If you experience any of the above side effects, contact your doctor immediately. Very common side effects (may affect more than 1 in 10 people): headache. Common side effects (may affect up to 1 in 10 people): dizziness, fatigue, rapid, irregular, or strong heartbeats (palpitations),
Uncommon side effects (may affect up to 1 in 100 people): weakness or feeling unwell, high blood pressure, irregular heart rhythm, fainting,
Rare side effects (may affect up to 1 in 1,000 people): gum bleeding, weight gain, severe chest pain (angina pectoris),
The following side effects have also been reported, but their frequency is unknown:
If you experience any side effects, including those not listed in this leaflet, tell your doctor or pharmacist, or nurse. Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products:
Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl. Side effects can also be reported to the marketing authorization holder. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep the medicine out of the sight and reach of children. Do not use this medicine after the expiry date stated on the label and carton after: EXP. The expiry date refers to the last day of the month. Anagrelide Vipharm, 0.5 mg, hard capsules. Do not store above 30°C. Store in the original package to protect from light and moisture. Anagrelide Vipharm, 1 mg, hard capsules. Do not store above 30°C. Store in the original package to protect from moisture. If your doctor tells you to stop taking the medicine, do not keep unused capsules unless your doctor tells you to. Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Anagrelide Vipharm, 0.5 mg, hard capsules
Anagrelide Vipharm, 1 mg, hard capsules
Anagrelide Vipharm, 0.5 mg, hard capsules Capsule shell:gelatin, titanium dioxide (E 171) Anagrelide Vipharm, 1 mg, hard capsules Capsule shell:gelatin, titanium dioxide (E 171), iron oxide black (E 172)
Anagrelide Vipharm 0.5 mg is a hard capsule (size 4, 14.3 x 5.3 mm) with a non-transparent white body and cap. Each capsule is filled with a white or almost white powder. Anagrelide Vipharm 1 mg is a hard capsule (size 4, 14.3 x 5.3 mm) with a gray body and cap. Each capsule is filled with a white or almost white powder. The capsules are supplied in bottles containing 42 or 100 hard capsules. Not all pack sizes may be marketed.
Marketing authorization holder Vipharm S.A. ul. A. i F. Radziwiłłów 9, 05-850 Ożarów Mazowiecki
Manufacturers/Importers Synthon Hispania, S.L. C/ Castelló no1, Pol. Las Salinas, Sant Boi de Llobregat, 08830 Barcelona, Spain Synthon BV Microweg 22, 6545 CM Nijmegen, Netherlands
Netherlands Anagrelide Genthon 0.5 mg / 1 mg, hard capsules Czech Republic Anagrelide Vipharm Spain Anagrelida Pharmavic 0.5 mg hard capsules EFG Finland Anagrelid Avansor 0.5 mg capsules, hard Croatia Anagrelid Alpha-Medical 0.5 mg hard capsules Hungary Anagrelide Vipharm Poland Anagrelide Vipharm Slovakia Anagrelide Vipharm 0.5 mg Sweden Anagrelid Avansor 0.5 mg hard capsules
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.